Understanding Alpha-1
An overview of alpha1 antitrypsin deficiency
Alpha-1 is a genetic condition caused by a lack of alpha1 antitrypsin, a protein
that counters the effects of an enzyme called neutrophil elastase. The primary function
of neutrophil elastase is to rid the lungs of germs and old or damaged cells. However,
if not properly regulated, neutrophil elastase can attack healthy lung tissue and
cause damage.1
- People who have Alpha-1 do not make enough alpha1 antitrypsin and are susceptible
to lung disease1
- Not all genetically predisposed individuals will develop clinically significant
symptoms1
- Alpha-1–associated emphysema can become chronic and weaken your lungs1
- Alpha-1 is more common than one might think, affecting all major racial subgroups
around the world2
- There are many services, resources, and treatments to help people with Alpha-1
CareZ™: Your home for help with Alpha-1
CSL Behring understands the impact that Alpha-1 can have on people, their lives,
and their families and loved ones. That is why CSL Behring provides CareZ, a comprehensive
suite of information and services that makes management of Alpha-1 easier. At CareZ,
you'll learn about:
- The causes of Alpha-1
- The symptoms of Alpha-1
- Who Alpha-1 affects
- How Alpha-1 is passed down through families
- Connect now to the valuable resources and support of the CareZ community
Is Treatment Available?
Important Safety Information
Alpha1-Proteinase Inhibitor (Human), Zemaira® is indicated for chronic augmentation and maintenance therapy for adults with alpha1-proteinase inhibitor (A1-PI) deficiency and emphysema. Clinical data demonstrating the long-term effects of chronic augmentation therapy with Zemaira are not available.
Zemaira may not be appropriate for the following adult individuals as they may experience severe reactions, including anaphylaxis: individuals with a known hypersensitivity and/or history of anaphylaxis or severe systemic reaction to A1-PI products or their components, and individuals with selective IgA deficiencies who have known antibodies against IgA.
In clinical studies, the following treatment-related adverse reactions were reported in 1% of subjects: asthenia (fatigue), injection-site pain, dizziness, headache, paresthesia (tingling), and pruritus (itching).
Zemaira is derived from human plasma. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.
Please see full prescribing information.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.